Nanotechnology Now

Our NanoNews Digest Sponsors

Heifer International

Wikipedia Affiliate Button

Home > Press > Arrowhead Announces Closing of $8.65 Million Registered Direct Offering

Abstract:
Arrowhead Research Corporation (NASDAQ: ARWR) today announced that it has closed its previously announced registered direct offering of 6.6 million shares of common stock and warrants to purchase 3.3 million shares of common stock.

Arrowhead Announces Closing of $8.65 Million Registered Direct Offering

Pasadena, CA | Posted on June 24th, 2010

Total proceeds from the offering were $8.65 million. The offering strengthens Arrowhead's balance sheet and enables continued progress with its current subsidiaries while also positioning the company to take advantage of new opportunities.

"Our lead subsidiaries, Calando and Unidym, are making significant progress and the current offering is important to continuing this momentum," said Christopher Anzalone, Arrowhead's CEO. "Calando's first ever demonstration of systemic siRNA delivery and gene silencing in humans was a considerable achievement, and our augmented balance sheet will better enable us to maximize its value by approaching potential partnerships from a position of strength. Similarly, Unidym has made great progress entering touch panel markets, and we are now in a better position to negotiate commercial alliances and strategic investments into that company. In addition, we are looking to ramp up our activity in nanomedicine by adding a new subsidiary to our portfolio and increasing our positions in our existing minority investments."

The stock and warrants were sold in units, at a price of $1.312 per unit, with each unit consisting of one share of common stock and a warrant to purchase one-half of one share of common stock. Oppenheimer & Co. Inc. was the sole placement agent for the offering. The warrants have an exercise price of $1.65 and are exercisable beginning December 23, 2010.

This press release does not constitute an offer to sell or a solicitation of an offer to buy the securities referred to herein, nor shall there be any sale of these securities in any state in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state.

The securities were issued under Arrowhead's shelf registration statement filed on Form S-3, which was declared effective by the Securities and Exchange Commission on June 11, 2010, and a prospectus supplement filed on June 18, 2010. The prospectus and prospectus supplement relating to this offering contain this and other information about the Company. The offering was made only by means of the prospectus and the related prospectus supplement, copies of which may be obtained from Oppenheimer & Co. Inc., Attn: Syndicate Prospectus Department, 300 Madison Ave., 4th Floor, New York, New York 10017, Phone (212) 667-8563, Fax (212) 667-6141, or

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995:

This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including the future success of our scientific studies, our ability to successfully develop products, rapid technological change in our markets, changes in demand for our future products, legislative, regulatory and competitive developments, the financial resources available to us, and general economic conditions. For example, there can be no assurance that Calando's clinical trials will be successful or that subsequent findings will be consistent with the initial findings. Arrowhead Research Corporation's most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q discuss some of the important risk factors that may affect our business, results of operations and financial condition. We disclaim any intent to revise or update publicly any forward-looking statements for any reason.

####

About Arrowhead Research Corporation
Arrowhead Research Corporation (www.arrowheadresearch.com) (NASDAQ: ARWR) is a nanotechnology company commercializing new technologies in the areas of life sciences and electronics. Arrowhead is seeking to build value for shareholders through the progress of its portfolio companies. Currently, Arrowhead is focused primarily on its two majority owned subsidiaries, Unidym, a leader in carbon nanotube technology for electronic applications, and Calando, at the forefront of clinical application of RNAi delivery technology. Arrowhead also has minority investments in two privately held nanobiotech companies.

Contacts:
Brandi Floberg
The Piacente Group, Inc.
212-481-2050

Copyright © Arrowhead Research Corporation

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Remote-control shoots laser at nano-gold to turn on cancer-killing immune cells April 20th, 2018

New qubit now works without breaks: A universal design for superconducting qubits has been created April 19th, 2018

Observing biological nanotransporters: Chemistry April 19th, 2018

Salt boosts creation of 2-D materials: Rice University scientists show how salt lowers reaction temperatures to make novel materials April 18th, 2018

Investments/IPO's/Splits

Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Marketplace Rule 5635(c)(4) March 20th, 2018

Nanometrics to Present at the 30th Annual ROTH Conference February 27th, 2018

180 Degree Capital Corp. Reports Net Asset Value per Share of $2.60 as of December 31, 2017; A Decrease of 3.0% From Prior Quarter and an Increase of 11.1% From December 31, 2016 February 27th, 2018

Nanowire LED Innovator Aledia Announces 30 ($36M) Million Series-C Financing: Intel Capital Joins Existing Investors to Commercialize Certain Nanowire-LED Technologies for Mobile Displays January 29th, 2018

Announcements

Remote-control shoots laser at nano-gold to turn on cancer-killing immune cells April 20th, 2018

New qubit now works without breaks: A universal design for superconducting qubits has been created April 19th, 2018

Observing biological nanotransporters: Chemistry April 19th, 2018

Salt boosts creation of 2-D materials: Rice University scientists show how salt lowers reaction temperatures to make novel materials April 18th, 2018

Financial Reports

Nanometrics to Announce First Quarter Financial Results on May 1, 2018 April 10th, 2018

180 Degree Capital Corp. Reports Net Asset Value per Share of $2.60 as of December 31, 2017; A Decrease of 3.0% From Prior Quarter and an Increase of 11.1% From December 31, 2016 February 27th, 2018

Arrowhead Pharmaceuticals to Webcast Fiscal 2018 First Quarter Results February 3rd, 2018

Nanometrics Announces Preliminary Results for the Third Quarter of 2017: Quarterly Results Impacted by Delays in Revenue Recognition on Multiple Systems into Japan October 12th, 2017

NanoNews-Digest
The latest news from around the world, FREE



  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project